{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:00:34Z","timestamp":1761562834536,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201810183C"],"award-info":[{"award-number":["HHSF223201810183C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40122-021-00343-z","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T05:02:50Z","timestamp":1638766970000},"page":"133-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-605X","authenticated-orcid":false,"given":"Nabarun","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryalice","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Lazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetla","family":"Slavova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"issue":"2","key":"343_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","volume":"108","author":"N Dasgupta","year":"2018","unstructured":"Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182\u20136.","journal-title":"Am J Public Health"},{"issue":"6","key":"343_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5055\/jom.2017.0415","volume":"13","author":"MD Dart","year":"2017","unstructured":"Dart MD, PhD RC, Iwanicki MDJL, Dasgupta PhDN, Cicero PhDTJ, Schnoll MD, PhD SH. Do abuse deterrent opioid formulations work? J Opioid Manag. 2017;13(6):365.","journal-title":"J Opioid Manag"},{"issue":"4","key":"343_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/papr.12760","volume":"19","author":"RL Rauck","year":"2019","unstructured":"Rauck RL. Mitigation of abuse through the use of abuse-deterrent opioid formulations: an overview of current technologies. Pain Pract. 2019;19(4):443\u201354.","journal-title":"Pain Pract"},{"key":"343_CR4","unstructured":"US Food and Drug Administration. Abuse-Deterrent Opioids - Evaluation and Labeling: Guidance for Industry [Internet]. 2015. https:\/\/www.fda.gov\/media\/84819\/download [cited 2021 Feb 2]."},{"key":"343_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/jrh.12496","volume":"37","author":"JR Brown","year":"2020","unstructured":"Brown JR, Gy Oh, Wang Y, Slavova S, Delcher C, Dasgupta N, et al. Variation in abuse-deterrent formulation opioid prescribing in California, Florida, and Kentucky in 2018. J Rural Health. 2020;37:23\u20138.","journal-title":"J Rural Health"},{"issue":"1","key":"343_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/00325481.2017.1268902","volume":"129","author":"LR Webster","year":"2017","unstructured":"Webster LR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgrad Med. 2017;129(1):102\u201310.","journal-title":"Postgrad Med"},{"issue":"2","key":"343_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clinthera.2018.01.003","volume":"40","author":"JP Cohen","year":"2018","unstructured":"Cohen JP, Mendoza M, Roland C. Challenges involved in the development and delivery of abuse-deterrent formulations of opioid analgesics. Clin Ther. 2018;40(2):334\u201344.","journal-title":"Clin Ther"},{"issue":"1","key":"343_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11926-008-0003-z","volume":"10","author":"N Katz","year":"2008","unstructured":"Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11\u20138.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"343_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40261-018-0651-3","volume":"38","author":"AJ Salwan","year":"2018","unstructured":"Salwan AJ, Hagemeier NE, Harirforoosh S. Abuse-deterrent opioid formulations: a key ingredient in the recipe to prevent opioid disasters? Clin Drug Investig. 2018;38(7):573\u20137.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"343_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","volume":"128","author":"RS Litman","year":"2018","unstructured":"Litman RS, Pag\u00e1n OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018;128(5):1015\u201326.","journal-title":"Anesthesiology"},{"issue":"1","key":"343_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/pmt-2019-0052","volume":"10","author":"AJ Carinci","year":"2020","unstructured":"Carinci AJ. Abuse-deterrent opioid analgesics: a guide for clinicians. Pain Manag. 2020;10(1):55\u201362.","journal-title":"Pain Manag"},{"issue":"6","key":"343_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1001\/jamainternmed.2015.0939","volume":"175","author":"HV Kunins","year":"2015","unstructured":"Kunins HV. Abuse-deterrent opioid formulations: part of a public health strategy to reverse the opioid epidemic. JAMA Intern Med. 2015;175(6):987.","journal-title":"JAMA Intern Med"},{"key":"343_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/JMDH.S166915","volume":"11","author":"JA Adler","year":"2018","unstructured":"Adler JA, Mallick-Searle T. An overview of abuse-deterrent opioids and recommendations for practical patient care. J Multidiscip Healthc. 2018;11:323\u201332.","journal-title":"J Multidiscip Healthc"},{"key":"343_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/JPR.S129553","volume":"10","author":"EJ Pezalla","year":"2017","unstructured":"Pezalla EJ, Rosen D, Erensen JG, Haddox JD, Mayne TJ. Secular trends in opioid prescribing in the USA. J Pain Res. 2017;10:383\u20137.","journal-title":"J Pain Res"},{"key":"343_CR15","unstructured":"Food and Drug Administration. FDA Briefing Information for the September 10\u201311, 2020 Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) [Internet]. https:\/\/www.fda.gov\/media\/141914\/download [cited 2021 Jan 22]."},{"issue":"12","key":"343_CR16","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","volume":"21","author":"S Geoffrey Severtson","year":"2020","unstructured":"Geoffrey Severtson S, Kreider SED, Amioka EC, Margolin ZR, Iwanicki JL, Dart RC. Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER. Pain Med. 2020;21(12):3660\u20138.","journal-title":"Pain Med"},{"key":"343_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102848","volume":"83","author":"ML Nolan","year":"2020","unstructured":"Nolan ML, Harocopos A, Allen B, Paone D. Reformulation of oxycodone 80 mg to prevent misuse: a cohort study assessing the impact of a supply-side intervention. Int J Drug Policy. 2020;83: 102848.","journal-title":"Int J Drug Policy"},{"key":"343_CR18","unstructured":"Williams B. Pfizer\u2019s opioid EMBEDA to be discontinued\u2014myMatrixx [Internet]. https:\/\/www.mymatrixx.com\/pfizers-opioid-embeda-to-be-discontinued\/ [cited 2021 Feb 2]"},{"key":"343_CR19","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2147\/JPR.S202376","volume":"12","author":"WM Hooten","year":"2019","unstructured":"Hooten WM, Dvorkin J, Warner NS, Pearson AC, Murad MH, Warner DO. Characteristics of physicians who prescribe opioids for chronic pain: a meta-narrative systematic review. JPR. 2019;12:2261\u201389.","journal-title":"JPR"},{"issue":"4","key":"343_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/pme.12352","volume":"15","author":"DC Turk","year":"2014","unstructured":"Turk DC, Dansie EJ, Wilson HD, Moskovitz B, Kim M. Physicians\u2019 beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients. Pain Med. 2014;15(4):625\u201336.","journal-title":"Pain Med"},{"issue":"4","key":"343_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/AJP.0000000000000268","volume":"32","author":"CS Hwang","year":"2016","unstructured":"Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Primary care physicians\u2019 knowledge and attitudes regarding prescription opioid abuse and diversion. Clin J Pain. 2016;32(4):279\u201384.","journal-title":"Clin J Pain"},{"issue":"1","key":"343_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1526-4637.2009.00737.x","volume":"11","author":"SF Butler","year":"2010","unstructured":"Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed \u201cabuse-deterrent\u201d prescription opioid formulation. Pain Med. 2010;11(1):81\u201391.","journal-title":"Pain Med"},{"issue":"1","key":"343_CR23","first-page":"21","volume":"13","author":"A Petrilla","year":"2020","unstructured":"Petrilla A, Marrett E, Shen X, Kwong WJ, Pezalla E. Association between formulary coverage and use of abuse-deterrent prescription opioids, risk for abuse or overdose, and associated healthcare resource utilization. Am Health Drug Benefits. 2020;13(1):21\u201331.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"343_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/pm\/pnx232","volume":"19","author":"A Brooks","year":"2018","unstructured":"Brooks A, Kominek C. ADF: abuse-deterrent formulation or another disillusioned formulation? Pain Med. 2018;19(5):907\u20139.","journal-title":"Pain Med"},{"key":"343_CR25","unstructured":"Institute for Clinical and Economic Review. Abuse-Deterrent Formulations of Opioids: Effectiveness and Value, Final Evidence Report [Internet]. 2017. http:\/\/icerorg.wpengine.com\/wp-content\/uploads\/2020\/10\/NECEPAC_ADF_Final_Report_08_08_17.pdf [cited 2021 Feb 2]."},{"issue":"4","key":"343_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jval.2018.12.005","volume":"22","author":"VM Kumar","year":"2019","unstructured":"Kumar VM, Agboola F, Synnott PG, Segel C, Webb M, Ollendorf DA, et al. Impact of abuse deterrent formulations of opioids in patients with chronic pain in the United States: a cost-effectiveness model. Value Health. 2019;22(4):416\u201322.","journal-title":"Value Health"},{"issue":"10","key":"343_CR27","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.pain.2012.05.029","volume":"153","author":"DC Turk","year":"2012","unstructured":"Turk DC, O\u2019Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain. 2012;153(10):1997\u20132008.","journal-title":"Pain"},{"issue":"3","key":"343_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/00325481.2019.1585688","volume":"131","author":"TJ Cicero","year":"2019","unstructured":"Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, et al. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgrad Med. 2019;131(3):225\u20139.","journal-title":"Postgrad Med"},{"issue":"4","key":"343_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577\u201381.","journal-title":"Stat Med"},{"issue":"2","key":"343_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1017\/S0266462300010370","volume":"13","author":"A Granados","year":"1997","unstructured":"Granados A, Jonsson E, Banta HD, Bero L, Bonair A, Cochet C, et al. EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care. 1997;13(2):220\u201386.","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"343_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/pds.4736","volume":"28","author":"N Dasgupta","year":"2019","unstructured":"Dasgupta N, Schwarz J, Hennessy S, Ertefaie A, Dart RC. Causal inference for evaluating prescription opioid abuse using trend-in-trend design. Pharmacoepidemiol Drug Saf. 2019;28(5):716\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"343_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF00314961","volume":"41","author":"P Denig","year":"1991","unstructured":"Denig P, Haaijer-Ruskamp FM, Wesseling H, Versluis A. Impact of clinical trials on the adoption of new drugs within a university hospital. Eur J Clin Pharmacol. 1991;41(4):325\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"343_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/01.ede.0000193606.58671.c5","volume":"17","author":"MA Brookhart","year":"2006","unstructured":"Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268\u201375.","journal-title":"Epidemiology"},{"issue":"4","key":"343_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1037\/0033-295X.92.4.548","volume":"92","author":"B Weiner","year":"1985","unstructured":"Weiner B. An attributional theory of achievement motivation and emotion. Psychol Rev. 1985;92(4):548\u201373.","journal-title":"Psychol Rev"},{"key":"343_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1037\/10628-000","volume-title":"The psychology of interpersonal relations","author":"F Heider","year":"1958","unstructured":"Heider F. The psychology of interpersonal relations. Hillsdale: Erlbaum; 1958. p. 322."},{"key":"343_CR36","volume-title":"Social cognition. McGraw-Hill series in social psychology","author":"ST Fiske","year":"1991","unstructured":"Fiske ST, Taylor SE. Social cognition. McGraw-Hill series in social psychology. New York: McGraw-Hill; 1991."},{"key":"343_CR37","unstructured":"Harvey P, Martinko MJ. Attribution theory and motivation. In: Organizational behavior, theory and design in health care. Jones and Bartlett Publishers; 2009. p. 143\u201358."},{"issue":"2","key":"343_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/00185860309598017","volume":"81","author":"NM Borkowski","year":"2003","unstructured":"Borkowski NM, Allen WR. Does attribution theory explain physicians\u2019 nonacceptance of clinical practice guidelines? Hosp Top. 2003;81(2):9\u201321.","journal-title":"Hosp Top"},{"issue":"3","key":"343_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/papt.12247","volume":"93","author":"M Zimmermann","year":"2020","unstructured":"Zimmermann M, Papa A. Causal explanations of depression and treatment credibility in adults with untreated depression: examining attribution theory. Psychol Psychother. 2020;93(3):537\u201354.","journal-title":"Psychol Psychother"},{"issue":"6","key":"343_CR40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/j.1532-2149.2013.00426.x","volume":"18","author":"MS Matthias","year":"2014","unstructured":"Matthias MS, Krebs EE, Bergman AA, Coffing JM, Bair MJ. Communicating about opioids for chronic pain: a qualitative study of patient attributions and the influence of the patient\u2013physician relationship. Eur J Pain. 2014;18(6):835\u201343.","journal-title":"Eur J Pain"},{"key":"343_CR41","unstructured":"Freeman PR, Brown JR, Maryalice N, Dasgupta N, Slavova S. Prescriber survey\u2014methodological advances in evaluating abuse-deterrent opioid analgesics. https:\/\/cdr.lib.unc.edu\/concern\/scholarly_works\/7h149z67n [cited 2021 Feb 2]."},{"issue":"2S","key":"343_CR42","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.japh.2016.12.064","volume":"57","author":"PR Freeman","year":"2017","unstructured":"Freeman PR, Goodin A, Troske S, Strahl A, Fallin A, Green TC. Pharmacists\u2019 role in opioid overdose: Kentucky pharmacists\u2019 willingness to participate in naloxone dispensing. J Am Pharm Assoc. 2017;57(2S):S28\u201333.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"343_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12954-018-0211-4","volume":"15","author":"A Goodin","year":"2018","unstructured":"Goodin A, Fallin-Bennett A, Green T, Freeman PR. Pharmacists\u2019 role in harm reduction: a survey assessment of Kentucky community pharmacists\u2019 willingness to participate in syringe\/needle exchange. Harm Reduct J. 2018;15(1):4.","journal-title":"Harm Reduct J"},{"issue":"3","key":"343_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.japh.2018.12.018","volume":"59","author":"J Blackmer","year":"2019","unstructured":"Blackmer J, Lindahl E, Strahl A, Schadler A, Freeman PR. Regulating gabapentin as a drug of abuse: a survey study of Kentucky community pharmacists. J Am Pharm Assoc. 2019;59(3):379\u201382.","journal-title":"J Am Pharm Assoc"},{"key":"343_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"343_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"1","key":"343_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.31887\/DCNS.2012.14.1\/jmarewski","volume":"14","author":"JN Marewski","year":"2012","unstructured":"Marewski JN, Gigerenzer G. Heuristic decision making in medicine. Dialogues Clin Neurosci. 2012;14(1):77\u201389.","journal-title":"Dialogues Clin Neurosci"},{"issue":"7","key":"343_CR48","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/jnci\/djz200","volume":"112","author":"LK Vitzthum","year":"2020","unstructured":"Vitzthum LK, Riviere P, Sheridan P, Nalawade V, Deka R, Furnish T, et al. Predicting persistent opioid use, abuse, and toxicity among cancer survivors. J Natl Cancer Inst. 2020;112(7):720\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"343_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1472-6963-12-18","volume":"23","author":"HM Kim","year":"2012","unstructured":"Kim HM, Smith EG, Stano CM, Ganoczy D, Zivin K, Walters H, et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res. 2012;23(12):18.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"343_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1472-6963-12-248","volume":"10","author":"AG Dunn","year":"2012","unstructured":"Dunn AG, Braithwaite J, Gallego B, Day RO, Runciman W, Coiera E. Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. BMC Health Serv Res. 2012;10(12):248.","journal-title":"BMC Health Serv Res"},{"issue":"8872","key":"343_CR51","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/0140-6736(93)91763-C","volume":"342","author":"W Inman","year":"1993","unstructured":"Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet. 1993;342(8872):658\u201361.","journal-title":"Lancet"},{"issue":"12","key":"343_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1472-6963-12-56","volume":"8","author":"FJ Garj\u00f3n","year":"2012","unstructured":"Garj\u00f3n FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by physicians: a survival analysis. BMC Health Serv Res. 2012;8(12):56.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"343_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00228-004-0797-1","volume":"60","author":"T Dybdahl","year":"2004","unstructured":"Dybdahl T, Andersen M, S\u00f8ndergaard J, Kragstrup J, Kristiansen IS. Does the early adopter of drugs exist? A population-based study of general practitioners? Prescribing of new drugs. Eur J Clin Pharmacol. 2004;60(9):667\u201372.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"343_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1155\/2014\/857952","volume":"19","author":"C Ringwalt","year":"2014","unstructured":"Ringwalt C, Gugelmann H, Garrettson M, Dasgupta N, Chung AE, Proescholdbell SK, et al. Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses. Pain Res Manag. 2014;19(4):179\u201385.","journal-title":"Pain Res Manag"},{"issue":"5","key":"343_CR55","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.amepre.2018.06.008","volume":"55","author":"GP Guy","year":"2018","unstructured":"Guy GP, Zhang K. Opioid prescribing by specialty and volume in the U.S. Am J Prev Med. 2018;55(5):e153\u20135.","journal-title":"Am J Prev Med"},{"issue":"3","key":"343_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.amepre.2015.02.020","volume":"49","author":"B Levy","year":"2015","unstructured":"Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic\u2014prescribing rates by specialty, U.S. 2007\u20132012. Am J Prev Med. 2015;49(3):409\u201313.","journal-title":"Am J Prev Med"},{"issue":"5","key":"343_CR57","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/pm\/pnx027","volume":"19","author":"SG Weiner","year":"2018","unstructured":"Weiner SG, Baker O, Rodgers AF, Garner C, Nelson LS, Kreiner PW, et al. Opioid prescriptions by specialty in Ohio, 2010\u20132014. Pain Med. 2018;19(5):978\u201389.","journal-title":"Pain Med"},{"key":"343_CR58","unstructured":"Food and Drug Administration. REMS Assessment: planning and reporting\u2014guidance for industry [Internet]. https:\/\/www.fda.gov\/media\/119790\/download [cited 2021 Feb 2]"},{"issue":"1","key":"343_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/08897077.2016.1265038","volume":"38","author":"S Chaudhary","year":"2017","unstructured":"Chaudhary S, Compton P. Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Subst Abus. 2017;38(1):95\u2013104.","journal-title":"Subst Abus"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-021-00343-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-021-00343-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-021-00343-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:11:28Z","timestamp":1676045488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-021-00343-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s40122-021-00343-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"type":"print","value":"2193-8237"},{"type":"electronic","value":"2193-651X"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"assertion":[{"value":"1 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}